Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles(Queen Mary University of London), Alain Ravaud(Bordeaux Population Health), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Marjorie C. Green, Daniel Castellano(Universidad Complutense de Madrid), Yohann Loriot(Institut Gustave Roussy), Michiel S. van der Heijden(Zorginstituut Nederland), Syed A. Hussain(University Hospitals Plymouth NHS Trust), Na Cui(Shanghai University), Ignacio Durán(Instituto de Biomedicina de Sevilla), Toshimi Takano(The Cancer Institute Hospital), Ning Leng, Aristotelis Bamias(National and Kapodistrian University of Athens), Romain Banchereau(Kaiser Permanente San Francisco Medical Center), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Gwénaëlle Gravis(Centre National de la Recherche Scientifique), Christina Louise Derleth, Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Edward E. Kadel, Xiaodong Shen(Fudan University), Aude Fléchon(Institut Català d'Ornitologia), Priti S. Hegde(Foundation Medicine (United States)), Margitta Retz(Arbeitsgemeinschaft Urologische Onkologie)
Cited by 1,413
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k